How much does ciprofloxacin hydrochloride and hydrocortisone cost?

Pricing for ciprofloxacin hydrochloride and hydrocortisone varies by insurance plan, dose, and pharmacy. Our database does not show a fixed cost because prices change faster than we can verify. For current pharmacy prices, check your insurance's formulary tier (in the prior-authorization section), use the GoodRx or Cost Plus Drugs deep links on this page, or ask your pharmacist to run a test claim. If a copay card is listed, it usually drops the out-of-pocket significantly for commercial insurance.

Does ciprofloxacin hydrochloride and hydrocortisone need prior authorization?

ciprofloxacin hydrochloride and hydrocortisone appears on 1 payer formulary in our database. PA requirements vary by payer — see the prior-authorization table on this page for specifics. In general, specialty and brand-name drugs are more likely to require PA than generic equivalents.

Is there a copay card or patient assistance program for ciprofloxacin hydrochloride and hydrocortisone?

We haven't verified an active copay card or PAP for ciprofloxacin hydrochloride and hydrocortisone in our current data. Check NeedyMeds or RxAssist for independent directories, or submit what you find via our "Report a broken link" form.

What is ciprofloxacin hydrochloride and hydrocortisone used to treat?

ciprofloxacin hydrochloride and hydrocortisone (generic: ciprofloxacin hydrochloride and hydrocortisone) is indicated for Acute Otitis Externa, Swimmer's Ear. Click any condition name on this page for more detail.

ciprofloxacin hydrochloride and hydrocortisone

Generic: ciprofloxacin hydrochloride and hydrocortisone

Verified·Apr 23, 2026

Manufacturer: Alcon
NDC: 0713-0851
RxCUI: 213320
Route: AURICULAR (OTIC)
ICD-10 indication: H60.339

Affordability Check

How much will you actually pay for ciprofloxacin hydrochloride and hydrocortisone?

In 30 seconds, see every legitimate way to afford ciprofloxacin hydrochloride and hydrocortisone — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.

Check my options →

About ciprofloxacin hydrochloride and hydrocortisone

What is this medication? This prescription medication is a combination ear drop that contains both an antibiotic and a corticosteroid. It is primarily indicated for the treatment of acute otitis externa, which is commonly known as swimmers ear. The ciprofloxacin hydrochloride component is a fluoroquinolone antibiotic that functions by eliminating the specific bacteria responsible for the infection in the outer ear canal.

The hydrocortisone component of the medication is a steroid that helps to alleviate the uncomfortable symptoms of the infection. It works by reducing redness, swelling, and itching in the affected area. By combining these two active ingredients, the medication effectively clears the bacterial infection while simultaneously providing relief from the inflammation and pain associated with the condition.

Copay & patient assistance

Detailed copay and financial assistance information is not publicly available for this medication at this time. Please consult your pharmacist or the manufacturer's official patient support program for more details.

External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.

Compare pricing elsewhere

RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.

Cost Plus Drug Company

Mark Cuban's transparent-pricing pharmacy — manufacturer cost + 15% markup + $5 dispensing fee. No insurance needed. Search alphabetically for ciprofloxacin hydrochloride and hydrocortisone.

Browse Cost Plus medications →

GoodRx

Compare local pharmacy prices with GoodRx coupons. Use the price with your insurance or without — whichever is cheaper.

Lookup ciprofloxacin hydrochloride and hydrocortisone →

NeedyMeds

Independent nonprofit directory of patient assistance programs, copay cards, and charity co-pay foundations.

Search for ciprofloxacin hydrochloride and hydrocortisone →

RxAssist

PAP directory maintained by Volunteers in Health Care at Brown University. Free, no ads.

Search PAPs →

We deep-link because transparency helps patients. None of these partners pay RxCopays.

Prescribing information

From the FDA-approved label for ciprofloxacin hydrochloride and hydrocortisone. Official source: DailyMed (NLM) · Label effective Dec 1, 2025

Indications and usage

INDICATIONS AND USAGE Ciprofloxacin hydrochloride and hydrocortisone otic suspension is indicated for the treatment of acute otitis externa in adult and pediatric patients, one year and older, due to susceptible strains of Pseudomonas aeruginosa , Staphylococcus aureus , and Proteus mirabilis .

Dosage and administration

DOSAGE AND ADMINISTRATION SHAKE WELL IMMEDIATELY BEFORE USING. For children (age 1 year and older) and adults, 3 drops of the suspension should be instilled into the affected ear twice daily for seven days. The suspension should be warmed by holding the bottle in the hand for 1-2 minutes to avoid the dizziness which may result from the instillation of a cold solution into the ear canal. The patient should lie with the affected ear upward and then the drops should be instilled. This position should be maintained for 30-60 seconds to facilitate penetration of the drops into the ear. Repeat, if necessary, for the opposite ear. Discard unused portion after therapy is completed.

Contraindications

CONTRAINDICATIONS Ciprofloxacin hydrochloride and hydrocortisone otic suspension is contraindicated in persons with a history of hypersensitivity to hydrocortisone, ciprofloxacin or any member of the quinolone class of antimicrobial agents. This nonsterile product should not be used if the tympanic membrane is known or suspected to be perforated. Use of this product is contraindicated in viral infections of the external canal including varicella and herpes simplex infections.

Warnings

WARNINGS NOT FOR OPHTHALMIC USE. NOT FOR INJECTION. Ciprofloxacin hydrochloride and hydrocortisone otic suspension should be discontinued at the first appearance of a skin rash or any other sign of hypersensitivity. Serious and occasionally fatal hypersensitivity (anaphylactic) reactions, some following the first dose, have been reported in patients receiving systemic quinolones. Serious acute hypersensitivity reactions may require immediate emergency treatment. The dropper cap contains natural rubber (latex) which may cause severe allergic reactions.

Adverse reactions

ADVERSE REACTIONS In Phase 3 clinical trials, a total of 564 patients were treated with ciprofloxacin hydrochloride and hydrocortisone otic suspension. Adverse events with at least remote relationship to treatment included headache (1.2%) and pruritus (0.4%). The following treatment-related adverse events were each reported in a single patient: migraine, hypesthesia, paresthesia, fungal dermatitis, cough, rash, urticaria, and alopecia. The following reactions have been identified during post-approval use of ciprofloxacin hydrochloride and hydrocortisone otic suspension in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The reactions, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to ciprofloxacin hydrochloride and hydrocortisone otic suspension, or a combination of these factors include: dizziness, ear canal erythema, ear congestion, hypoacusis and medication residue. To report SUSPECTED ADVERSE REACTIONS, contact Cosette Pharmaceuticals, Inc. at 1-800-922-1038 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

Use in pregnancy

Pregnancy: Teratogenic Effects: Reproduction studies have been performed in rats and mice using oral doses of up to 100 mg/kg and IV doses up to 30 mg/kg and have revealed no evidence of harm to the fetus as a result of ciprofloxacin. In rabbits, ciprofloxacin (30 and 100 mg/kg orally) produced gastrointestinal disturbances resulting in maternal weight loss and an increased incidence of abortion, but no teratogenicity was observed at either dose. After intravenous administration of doses up to 20 mg/kg, no maternal toxicity was produced in the rabbit, and no embryotoxicity or teratogenicity was observed. Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. Animal reproduction studies have not been conducted with ciprofloxacin hydrochloride and hydrocortisone otic suspension. No adequate and well controlled studies have been performed in pregnant women. Caution should be exercised when ciprofloxacin hydrochloride and hydrocortisone otic suspension is used by a pregnant woman.

Label text is reproduced as-is from the FDA-approved label. We do not paraphrase, summarize, or omit. Content above is for informational purposes only and is not medical advice. Always consult your prescribing clinician or pharmacist before making decisions about your medication.

Conditions we've indexed resources for

Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.

Medicare Part D coverage

How ciprofloxacin hydrochloride and hydrocortisone appears across Medicare Part D plan formularies nationally. Source: CMS monthly Prescription Drug Plan file (2026-04-30).

Covered by plans

31%

1,682 of 5,509 plans

Most common tier

Tier 4

On 67% of covering formularies

Prior authorization required

of covering formularies

Tier	Formularies on this tier	Share
Tier 1 (preferred generic)	1	4%
Tier 2 (generic)	2	7%
Tier 3 (preferred brand)	6	22%
Tier 4 (non-preferred brand)	18	67%

Step therapy: 0% of formularies

Quantity limits: 0% of formularies

Coverage breadth: 27 of 65 formularies

How to read this:plans on the same formulary share tier + PA rules. Your specific plan's copay depends on (a) the tier above, (b) your plan's cost-share for that tier, (c) whether you're in the initial coverage phase or past the 2026 $2,000 out-of-pocket cap. For your exact plan, check its Summary of Benefits or log in to your Medicare.gov account. Copay cards don't apply to Medicare (federal law).

Prior authorization & coverage

Payer	PA	Step therapy	Copay tier
— Medicare Part D	—	—	—

Payer

Step therapy

Copay tier

—

Medicare Part D

—

Related drugs

How this page is sourced

Drug identity verified against openFDA NDC Directory.
Label text (when shown) originates from NLM DailyMed.
Copay and assistance URLs verified periodically; if you hit a broken link, tell us.